Mirum Pharmaceuticals Stock Soars as Revenue Jumps 56.8% in 2025

Mirum Pharmaceuticals has witnessed remarkable growth in recent times, with its stock price more than doubling. The biotech company, specializing in treatments for rare and underserved diseases, now commands a market capitalization of approximately $4.69 billion. Robust revenue increases and strategic maneuvers have propelled its shares to unprecedented heights.

The company's revenue surged by 56.8% during the first nine months of 2025, reaching $372.4 million. For the full year, net product sales are projected to reach $520 million, indicating a growth of at least 54.4% compared to 2024. Analysts remain bullish, with price targets as high as $140 per share.

In late 2025, Mirum reported its first quarterly profit in years, posting a net gain of $2.9 million in Q3. This marked a significant turnaround from the $14.2 million loss recorded in the same period a year earlier. Losses per share also narrowed considerably, dropping from $1.36 to $0.35 over the first nine months of 2025.

The firm's growth strategy encompasses acquisitions, such as the $620 million purchase of Bluejay Therapeutics. That deal, which could reach $820 million with milestone payments, aims to expand Mirum's pipeline. Looking ahead, the company forecasts 2026 sales between $630 million and $650 million, representing another 23.1% increase.

Despite progress, consistent profitability remains uncertain. Investors are now closely watching upcoming clinical trials, which could further influence the stock's performance.

Mirum's market value has climbed from its 2019 IPO levels to nearly $4.7 billion, driven by revenue growth and strategic deals. With sales projections rising and key clinical updates on the horizon, the company's next moves will determine whether it can maintain long-term profitability.